Related Experiment Video

Updated: May 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

The changing landscape in the treatment of metastatic castration-resistant prostate cancer

Joelle El-Amm1, Jeanny B Aragon-Ching

  • 1Division of Hematology and Oncology, Department of Medicine, George Washington University Medical Center, Washington, DC, USA.

Therapeutic Advances in Medical Oncology
|January 17, 2013
PubMed

Insights

Recent advances offer new treatments for metastatic castration-resistant prostate cancer. This review covers clinical trials and suggests optimal sequencing strategies for these novel therapies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) management has evolved with new therapeutic approvals.
  • Several agents, including sipuleucel-T, cabazitaxel, denosumab, and abiraterone acetate, are now available.
  • Emerging therapies like MDV3100 and alpharadin show promising results.

Purpose of the Study:

  • To review clinical trials leading to recent drug approvals for mCRPC.
  • To provide insights into rational treatment sequencing due to a lack of national guidelines.

Main Methods:

  • Review of clinical trial data for approved mCRPC agents.
  • Analysis of emerging drug pipeline data.
  • Synthesis of information to propose treatment sequencing strategies.

Main Results:

  • Multiple therapeutic options now exist for mCRPC, including immunotherapy, chemotherapy, bone-targeted agents, and novel antiandrogens.
  • Ongoing research and development are yielding promising new agents.
  • Clinical trial evidence supports the efficacy of these diverse treatment modalities.

Conclusions:

  • The therapeutic landscape for mCRPC has significantly expanded.
  • Optimal sequencing of these agents is crucial for patient outcomes.
  • Further research is needed to establish definitive treatment guidelines.
Keywords:
Androgen deprivation therapychemotherapymetastatic castration-resistant prostate cancervaccine therapy

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...